Anzeige
Mehr »
Sonntag, 15.02.2026 - Börsentäglich über 12.000 News
FRIEDLANDS 10.000-JAHRE-SCHOCK: Der Kupfer-Engpass hat begonnen
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
649 Leser
Artikel bewerten:
(2)

Scivita Medical enters into Strategic Agreement with Boston Scientific in China

SUZHOU, China, March 29, 2023 /PRNewswire/ -- Medical technology company Scivita Medical Technology Co., Ltd. ('Scivita Medical') and Boston Scientific (NYSE: BSX), one of the leading medical technology companies worldwide, have officially signed a Strategic Agreement forScivita's Single-Use Percutaneous Choledochoscope. Through this business cooperation and distribution agreement, Scivita Medical and Boston Scientific plan to establish a long-term partnership in the commercialization, marketing and promotion of Scivita's Single-Use Percutaneous Choledochoscope in China.

Signing ceremony

Under Scivita Medical's comprehensive product lineup of reusable endoscopes, single-use videoscopes and related systems and equipment, this cooperation further broadens its market penetration of its Single-Use Percutaneous Choledochoscope. Through the strong alliance with Boston Scientific, the penetration rate of the Single-Use Percutaneous Choledochoscope in China is expected to increase benefiting more hospitals and patients.

Single-Use Percutaneous Choledochoscope

Scivita Medical said, 'Thanks to Boston Scientific for its recognition of Scivita Medical. This is another important initiative for Scivita Medical in establishing its vision of becoming a global company, and another milestone following its strategic cooperation with Fujifilm for the European market. I believe this strategic cooperation with some of the world's leading medical technology companies and our company will accelerate the process of bringing China's medical innovations to the world.'

As a result of the growing demands of mitigating the risks of cross-contamination and hospital-acquired diseases, particularly amid the outbreak of COVID-19 pandemic, the global single-use videoscope market is also rapidly growing. The global market value of single-use videoscope was USD 0.5 billion in 2020, and is estimated to increase to USD 9.2 billion in 2030, according to Frost & Sullivan. Scivita Medical's single-use videoscopes have covered multiple clinical departments at a high risk of cross-infection, such as Gynecology, Respiratory, Urological Surgery and Hepatobiliary Surgery. Many of its products have already been approved in China, the United States, European Union (EU), Japan and other countries and regions.

Scivita Medical New Plant

This cooperation can be seen as strong evidence of Scivita Medical's comprehensive product lineup of reusable endoscopes, single-use videoscope and related systems and equipment, which further accelerates its commercialization and penetration in the field of single-use videoscope. In the future, Scivita Medical will further strengthen its innovation, improve market penetration by offering unique products and strive to become the preferred brand for doctors and patients worldwide.

About Scivita Medical

Founded in 2016, Scivita Medical is a medical device company that provides minimally invasive diagnosis and treatment solutions, and focuses on research, development and commercialization of medical endoscopes and related products. Scivita Medical takes 'Globalization' as its core strategy and has established R&D centers both in China and Japan. With solid in-house R&D capabilities, Scivita Medical has established a unique technology platform built upon five synergistic core technologies, and built a comprehensive portfolio of endoscope products and therapeutic products covering all types of endoscope procedures conducted by the various clinical departments, to address diverse medical needs. Adhering to its value of 'Clinical Focus' 'Collaborative Innovation' 'People Oriented' 'Excellence & Efficiency', Scivita Medical will continuously upgrade its core technologies, improve market penetration with excellent products aiming to become the preferred brand, trusted by doctors and patients around the world.

For more information, please visit: scivitamedical.com/#/

Photo - https://mma.prnewswire.com/media/2043103/Signing_ceremony.jpg
Photo - https://mma.prnewswire.com/media/2043104/Single_Use_Percutaneous_Choledochoscope.jpg
Photo - https://mma.prnewswire.com/media/2043105/1.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/scivita-medical-enters-into-strategic-agreement-with-boston-scientific-in-china-301784636.html

© 2023 PR Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.